Showing results (171-180 of 330) with videos related to
Sort By:
Pageof 33
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 9, 2012
Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29Monika Kwiecinski, Natalia Elfimova, Andrea Noetel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junctionHinrich A Wieder, Ambros J Beer, Florian Lordick, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 3, 2013
Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosisUlrike Heger, Franz Bader, Florian Lordick, et al.Annals of Surgical Oncology|November 28, 2013
A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapyRupert Langer, Karen Becker, Inti Zlobec, et al.Gastro Hep Advances|May 11, 2026
Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-AnalysisFlorian Lordick, Efrat Dotan, Lin Zhan, et al.Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|September 8, 2025
Quality indicator survey of clinical practice guidelines for esophagogastric junction cancer 2023Satoru Matsuda, Bas Wijnhoven, Florian Lordick, et al.Langenbeck'S Archives of Surgery|December 28, 2012
Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumorKatja Ott, Susanne Blank, Karen Becker, et al.British Journal of Cancer|January 24, 2024
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancerJun Wang, Na Sun, Thomas Kunzke, et al.International Journal of Molecular Sciences|August 7, 2021
Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor TherapyRobin Reschke, Philipp Gussek, Andreas Boldt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patientsRudolf Napieralski, Katja Ott, Markus Kremer, et al.Pageof 33